secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055645
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics Q1 net loss $11.1M; cash $270.7M; advancing DT-216P2, DT-168, HD, DM1 programs
--------------------------------------------------------------------------------

- Net loss of $11.1M for Q1 2024; R&D expenses $9.8M, G&A expenses $4.6M.
- Cash and securities $270.7M as of March 31, 2024; expected funding into 2029.
- DT-216P2 for Friedreich Ataxia: GLP studies by year-end 2024; patient trials start 2025.
- DT-168 for FECD: Phase 1 development expected to start in 2024; observational study enrolling 200 patients.
- GeneTAC pipeline: HD and DM1 programs advancing toward development candidates; preclinical data showed mutant gene knockdown.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017024055645/0000950170-24-055645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017024055645/dsgn-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer